Regions Financial Corp’s Lexicon Pharmaceuticals LXRX Stock Holding History

Regions Financial Corp’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-74	Closed	–	–	1340
2019 Q1	$0	Hold	74	–	–	﹤0.01%	1992
2018 Q4	$0	Hold	74	–	–	﹤0.01%	1954
2018 Q3	$1K	Hold	74	–	–	﹤0.01%	1909
2018 Q2	$1K	Buy	+74	New	+$757	﹤0.01%	2003

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Regions Financial Corp's LXRX Position: Q2 2019 in Review

Regions Financial Corp sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2019, closing a stake of 74 shares.

Regions Financial Corp first reported a position in LXRX in Q2 2018 and held it in 4 quarters. The position peaked at $1K in Q3 2018. 109 funds tracked by Wall St. Rank hold LXRX as of Q2 2019.

Regions Financial Corp reported no remaining Lexicon Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Regions Financial Corp sold 74 Lexicon Pharmaceuticals shares in Q2 2019.
Regions Financial Corp first reported a position in Lexicon Pharmaceuticals in Q2 2018 and held it in 4 quarters.
Regions Financial Corp's Lexicon Pharmaceuticals position peaked at $1K in Q3 2018.
109 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2019.

Based on Regions Financial Corp's 13F filing for Q2 2019, filed 19 Jul 2019.